Quintiles has been named the market leader in Phase IV services for the third year in a row. That’s according to the 2015 CRO Quality Benchmarking – Phase IV Service Providers Report from Industry Standard Research (ISR).
Quintiles was selected as the preferred provider among biopharmaceutical companies for Phase IV services based on a survey of 110 global biopharmaceutical representatives. Phave IV monitored are aimed at addressing drug product success after regulartory approval.
Quintiles was highlighted as a leader across a number of key service quality metrics, including its service breadth, global footprint and technology that enables real-time data access delivered by its award-winning Quintiles Infosario® platform.
Top performer in these categories
Compared to the other 33 Phase IV Contract Research Organizations noted in the report, Quintiles was a top performer in a number of selection criteria including:
- · Leadership
- · Preference
- · Customer loyalty
- · Performance relative to expectations
- · Perceived differentiation of service quality
Survey participants were decision-makers from small, mid-size and large global biopharmaceutical companies and were required to have been involved in outsourced Phase IV trials within the past 18 months.
To learn more about the report see: http://www.isrreports.com/reports/cro-quality-benchmarking-phase-iv-service-providers-7th-edition/
